BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...

BioNTech is back in Wall Street’s spotlight after posting better-than-expected second-quarter results and doubling down on ...

This article will be updated throughout the day, so check back often for more daily updates. Last week ended on a down note — and a 2.4% weekly loss for the Vanguard S&P 500 ETF (NYSEMKT: VOO) — as a ...

CAMBRIDGE, MA / ACCESS Newswire / August 1, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the UK Court of Appeal ...

BioNTech SE BNTX +3.21% Get Free Report reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus ...

The company expects that the U.S. COVID-19 vaccination rate will be “maybe a couple of points lower” than the prior level of ...

BioNTech’s second-quarter earnings came in at a loss of 1.60 euros a share on revenue of €261 million ($302.1 million), ...

BioNTech (BNTX) stock gains as the company surpasses Q2 2025 forecasts with 103% YoY revenue growth, thanks mainly to Pfizer ...

BioNTech said a partnership with Bristol Myers Squibb is expected to further strengthen its financial position with $1.5 billion expected to be reflected in its cash position for the current quarter.

German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million ...

UK Court of Appeal upholds key Moderna patent against Pfizer and BioNTech | Comirnaty vaccine ruled to infringe European mRNA technology patent. Already registered? If you don't have a login or your ...

HHS Secretary Robert F. Kennedy Jr. has upended the way Covid vaccines are approved and for whom they’re recommended, ...